Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Clonal Architecture of TET2 Mutations Influences the Clinical Phenotype of Patients with Myeloid Neoplasms

Cassandra M. Hirsch, BS, Aziz Nazha, MD, Kneen Kassy, Manja Meggendorfer, PhD, Bartlomiej P. Przychodzen, MSc, Niroshan Nadarajah, Vera Adema, PhD, Yasunobu Nagata, MD PhD, Valeria Visconte, PhD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Ryszard Ólinski, Professor, Sudipto Mukherjee, MD PhD MPH, Babal K Jha, PhD, Thomas Laframboise, PhD, Tomas Radivoyevitch, PhD, Torsten Haferlach, MD, Jaroslaw P. Maciejewski, PhD MD FACP

Blood (2017) 130 (Supplement 1): 4228.

https://doi.org/10.1182/blood.V130.Suppl_1.4228.4228

Published: 2017

Journal Articles

Activation of Autophagy in Models of SF3B1 Mutant MDS

Blood (2017) 130 (Supplement 1): 4230.

https://doi.org/10.1182/blood.V130.Suppl_1.4230.4230

Published: 2017

Journal Articles

PPM1D Mutations and up Modulation Phenocopy TP53 Lesions in Myeloid Neoplasms

Reem Elagooz, MS, MD, Mai Aly, MD MS, Cassandra M. Hirsch, BS, Bartlomiej P. Przychodzen, MSc, Teodora Kuzmanovic, BA, Tomas Radivoyevitch, Valeria Visconte, PhD, Sudipto Mukherjee, MD PhD MPH, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Aziz Nazha, MD, Jaroslaw P. Maciejewski, PhD MD FACP, Yasunobu Nagata, MD PhD

Blood (2017) 130 (Supplement 1): 4233.

https://doi.org/10.1182/blood.V130.Suppl_1.4233.4233

Published: 2017

Journal Articles

Mutational Signatures Associated with Intensity and Duration of Smoking in Myelodysplastic Syndromes (MDS)

Yazan F. Madanat, MD, Tomas Radivoyevitch, PhD, Aziz Nazha, MD, Yazeed Sawalha, MD, Karam Al-Issa, MD, Nour Abuhadra, MD, Teodora Kuzmanovic, BA, Bartlomiej Przychodzen, Cassandra M. Hirsch, BS, Bhumika J. Patel, MD, David Seastone, PhDDO, Yogenthiran Saunthararajah, MD, Sudipto Mukherjee, MD PhD MPH, Anjali S. Advani, MD, Hetty E. Carraway, MD MBA, Aaron T. Gerds, MDMS, Jaroslaw P. Maciejewski, PhD MD FACP, Mikkael A. Sekeres, MD MS

Blood (2017) 130 (Supplement 1): 424.

https://doi.org/10.1182/blood.V130.Suppl_1.424.424

Published: 2017

Journal Articles

Distinct Genomic Associations to Predict Acute Myeloid Leukemia (AML) Progression from Myelodysplastic Syndromes (MDS)

Yazan F. Madanat, MD, Mikkael A. Sekeres, MD MS, Karam Al-Issa, MD, Cassandra M. Hirsch, BS, Sudipto Mukherjee, MD PhD MPH, Aaron T. Gerds, MDMS, Nour Abuhadra, MD, Babal K Jha, PhD, Vera Adema, PhD, Anjali S. Advani, MD, Yasunobu Nagata, MD PhD, Teodora Kuzmanovic, BA, Bartlomiej P. Przychodzen, MSc, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, PhD MD FACP, Aziz Nazha, MD

Blood (2017) 130 (Supplement 1): 4245.

https://doi.org/10.1182/blood.V130.Suppl_1.4245.4245

Published: 2017

Journal Articles

Extent and Clinical Implications of Subclonal Diversity in Paroxysmal Nocturnal Hemoglobinuria

Mohammad Fahad B Asad, MD MBBS, Abhinav Goyal, MD, Hassan Awada, MD, Mai Aly, Cassandra Hirsch, Michael J. Clemente, Aziz Nazha, MD, Hetty E. Carraway, MD MBA, Sudipto Mukherjee, MD PhD MPH, Yasunobu Nagata, MD PhD, Jaroslaw P. Maciejewski, PhD MD FACP

Blood (2017) 130 (Supplement 1): 779.

https://doi.org/10.1182/blood.V130.Suppl_1.779.779

Published: 2017

Journal Articles

Therapeutic Targeting of GLI1 in Acute Myeloid Leukemia

Metis Hasipek, PhD, Sayer Al-Harbi, PhD, James G Phillips, PhD, Bartlomiej P. Przychodzen, MSc, Alek Nielsen, BS, Yihong Guan, PhD, Dale Grabowski, BS, Phillip J Maciejewski, Aziz Nazha, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, PhD MD FACP, Babal K Jha, PhD

Blood (2017) 130 (Supplement 1): 2654.

https://doi.org/10.1182/blood.V130.Suppl_1.2654.2654

Published: 2017

Journal Articles

Surveillance of the Immune Repertoire of Aplastic Anemia Patients Using Deep Sequencing

Cassandra M. Hirsch, BS, Michael J. Clemente, Valeria Visconte, PhD, Taha Bat, Bartlomiej P. Przychodzen, MSc, Tomas Radivoyevitch, PhD, Vera Adema, PhD, Yasunobu Nagata, MD PhD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Babal K Jha, PhD, Sudipto Mukherjee, MD PhD MPH, Thomas Laframboise, PhD, Jaroslaw P. Maciejewski, PhD MD FACP

Blood (2017) 130 (Supplement 1): 2454.

https://doi.org/10.1182/blood.V130.Suppl_1.2454.2454

Published: 2017

Journal Articles

Mutations in DNMT3A , U2AF1 , and EZH2 Identify Intermediate-Risk Acute Myeloid Leukemia Patients with Poor Outcome after CR1

Caner Saygin, MD, Cassandra M. Hirsch, BS, Bartlomiej Przychodzen, M.S., Mikkael A. Sekeres, MD MS, Betty K. Hamilton, MD, Matt Kalaycio, MD, Hetty E. Carraway, MD MBA, Aaron T. Gerds, MDMS, Sudipto Mukherjee, MD PhD MPH, Aziz Nazha, MD, Ronald Sobecks, MD, Christopher Goebel, Donna M. Abounader, Jaroslaw P. Maciejewski, PhD MD FACP, Anjali S. Advani, MD

Blood (2017) 130 (Supplement 1): 2665.

https://doi.org/10.1182/blood.V130.Suppl_1.2665.2665

Published: 2017

Journal Articles

How Somatic Mutations Carve Morphologic Imprint in MDS?

Abhinav Goyal, MD, Mohammad Fahad B Asad, MD MBBS, Hassan Awada, MD, Mai Aly, MD, Cassandra M. Hirsch, BS, Bartlomiej P. Przychodzen, MSc, Tomas Radivoyevitch, PhD, Aziz Nazha, MD, Sudipto Mukherjee, MD PhD MPH, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, PhD MD FACP, Yasunobu Nagata, MD PhD

Blood (2017) 130 (Supplement 1): 2949.

https://doi.org/10.1182/blood.V130.Suppl_1.2949.2949

Published: 2017

Journal Articles

Distinct Clinical Phenotypes of Patients with Myeloid Neoplasms Carrying SF3B1 Hotspot Mutations

Blood (2017) 130 (Supplement 1): 2961.

https://doi.org/10.1182/blood.V130.Suppl_1.2961.2961

Published: 2017

Journal Articles

Atherosclerotic Arterial Disease-Related Mortality in Chronic Myeloid Patients Treated with Tyrosine Kinase Inhibitors

Remco J Molenaar, Tomas Radivoyevitch, Aziz Nazha, MD, Anjali S. Advani, MD, Aaron T. Gerds, MDMS, Jaroslaw P. Maciejewski, PhD MD FACP, Navneet S. Majhail, MD MS, Mikkael A. Sekeres, MD MS, Matt Kalaycio, MD, Sudipto Mukherjee, MD PhD MPH

Blood (2017) 130 (Supplement 1): 2871.

https://doi.org/10.1182/blood.V130.Suppl_1.2871.2871

Published: 2017

Journal Articles

No Excess Risk of Second Malignancies in Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosine Kinase Inhibitors (TKIs)

Lilian Iglesias, Sudipto Mukherjee, MD PhD MPH, Aziz Nazha, MD, Anjali S. Advani, MD, Aaron T. Gerds, MDMS, Hetty E. Carraway, MD MBA, Matt Kalaycio, MD, Jaroslaw P. Maciejewski, PhD MD FACP, Navneet S. Majhail, MD MS, Mikkael A. Sekeres, MD MS

Blood (2017) 130 (Supplement 1): 2872.

https://doi.org/10.1182/blood.V130.Suppl_1.2872.2872

Published: 2017

Journal Articles

Prediction of Clinically Relevant Mutations in (MDS): A Report on Behalf of the MDS Clinical Research Consortium (CRC)

Sangmin Lee, MD, John Barnard, PhD, Rami S. Komrokji, MD, Amy E. DeZern, MD, David P. Steensma, MD, Jaroslaw P. Maciejewski, PhD MD FACP, Ellen K Ritchie, MD, Pinkal Desai, MDMPH, Felix Tavernier, MD, Duane C. Hassane, PhD, Guillermo Garcia-Manero, MD, Mikkael A. Sekeres, MD MS, Gail J. Roboz, MD

Blood (2017) 130 (Supplement 1): 2965.

https://doi.org/10.1182/blood.V130.Suppl_1.2965.2965

Published: 2017

Journal Articles

Model Heterogeneity in Predicting Outcomes of Patients with Myelodysplastic Syndromes (MDS)

Karam Al-Issa, MD, Yazan F. Madanat, MD, Sudipto Mukherjee, MD PhD MPH, Cassandra M. Hirsch, BS, Aaron T. Gerds, MDMS, Nour Abuhadra, MD, Ahed Makhoul, MD, Hassan Awada, MD, Mohammad Fahad B Asad, MD MBBS, Abhinav Goyal, MD, Anjali S. Advani, MD, Teodora Kuzmanovic, BA, Bartlomiej P. Przychodzen, MSc, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, PhD MD FACP, Mikkael A. Sekeres, MD MS, Aziz Nazha, MD

Blood (2017) 130 (Supplement 1): 2972.

https://doi.org/10.1182/blood.V130.Suppl_1.2972.2972

Published: 2017

Journal Articles

The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy

Xiaorong Gu, PhD, Quteba Ebrahem, MD, Reda Z. Mahfouz, MD PhD, Metis Hasipek, PhD, Francis Enane, PhD, Tomas Radivoyevitch, Nicolas Rapin, PhDMSc, Bartlomiej P. Przychodzen, MSc, Ramesh Balusu, PhD, Claudiu V Cotta, David Wald, MD PhD, Zhenbo Hu, MD PhD, Yosef Landesman, PhD, Maria Paola Martelli, MD PhD, Brunangelo Falini, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, PhD MD FACP, Babal K Jha, PhD, Yogenthiran Saunthararajah, MD

Blood (2017) 130 (Supplement 1): 878.

https://doi.org/10.1182/blood.V130.Suppl_1.878.878

Published: 2017

Journal Articles

A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes (MDS)

Aziz Nazha, MD, Rami S. Komrokji, MD, John Barnard, PhD, Karam Al-Issa, MD, Eric Padron, MD, Yazan F. Madanat, MD, Teodora Kuzmanovic, BA, Nour Abuhadra, MD, David P. Steensma, MD, Amy E. DeZern, MD, Gail J. Roboz, MD, Guillermo Garcia-Manero, MD, Alan F. List, MD, Jaroslaw P. Maciejewski, PhD MD FACP, Mikkael A. Sekeres, MD MS

Blood (2017) 130 (Supplement 1): 160.

https://doi.org/10.1182/blood.V130.Suppl_1.160.160

Published: 2017

Journal Articles

Clinical and Molecular Characteristics of Therapy-Related Acute Lymphoblastic Leukemia

Blood (2017) 130 (Supplement 1): 3993.

https://doi.org/10.1182/blood.V130.Suppl_1.3993.3993

Published: 2017

Journal Articles

Genomic Biomarkers to Predict Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS)

Aziz Nazha, MD, Mikkael A. Sekeres, MD MS, Rafael Bejar, MD PhD, Rami S. Komrokji, MD, John Barnard, PhD, Karam Al-Issa, MD, Bartlomiej P. Przychodzen, MSc, Cassandra M. Hirsch, BS, David P. Steensma, MD, Amy E. DeZern, MD, Gail J. Roboz, MD, Guillermo Garcia-Manero, MD, Benjamin L. Ebert, MD PhD, Jaroslaw P. Maciejewski, PhD MD FACP

Blood (2017) 130 (Supplement 1): 157.

https://doi.org/10.1182/blood.V130.Suppl_1.157.157

Published: 2017

Journal Articles

Targeting the MALAT1/PARP1/LIG3 Complex Induces DNA Damage and Apoptosis in Multiple Myeloma Mouse Models

Yi Hu, Jing Fang, Hua Fang, Chen Li, Shuang Liu, Sarah L. Ondrejka, MD, Zihua Gong, Jaroslaw P. Maciejewski, PhD MD FACP, Frederic J. Reu, MD, Qing Yi, MD PhD, Jianjun Zhao, MD

Blood (2017) 130 (Supplement 1): 1829.

https://doi.org/10.1182/blood.V130.Suppl_1.1829.1829

Published: 2017

NARROW

Clonal Architecture of TET2 Mutations Influences the Clinical Phenotype of Patients with Myeloid Neoplasms

Activation of Autophagy in Models of SF3B1 Mutant MDS

PPM1D Mutations and up Modulation Phenocopy TP53 Lesions in Myeloid Neoplasms

Mutational Signatures Associated with Intensity and Duration of Smoking in Myelodysplastic Syndromes (MDS)

Distinct Genomic Associations to Predict Acute Myeloid Leukemia (AML) Progression from Myelodysplastic Syndromes (MDS)

Extent and Clinical Implications of Subclonal Diversity in Paroxysmal Nocturnal Hemoglobinuria

Therapeutic Targeting of GLI1 in Acute Myeloid Leukemia

Surveillance of the Immune Repertoire of Aplastic Anemia Patients Using Deep Sequencing

Mutations in DNMT3A , U2AF1 , and EZH2 Identify Intermediate-Risk Acute Myeloid Leukemia Patients with Poor Outcome after CR1

How Somatic Mutations Carve Morphologic Imprint in MDS?

Distinct Clinical Phenotypes of Patients with Myeloid Neoplasms Carrying SF3B1 Hotspot Mutations

Atherosclerotic Arterial Disease-Related Mortality in Chronic Myeloid Patients Treated with Tyrosine Kinase Inhibitors

No Excess Risk of Second Malignancies in Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosine Kinase Inhibitors (TKIs)

Prediction of Clinically Relevant Mutations in (MDS): A Report on Behalf of the MDS Clinical Research Consortium (CRC)

Model Heterogeneity in Predicting Outcomes of Patients with Myelodysplastic Syndromes (MDS)

The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy

A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes (MDS)

Clinical and Molecular Characteristics of Therapy-Related Acute Lymphoblastic Leukemia

Genomic Biomarkers to Predict Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS)

Targeting the MALAT1/PARP1/LIG3 Complex Induces DNA Damage and Apoptosis in Multiple Myeloma Mouse Models

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only